Handelsbanken Fonder AB Takes $1.04 Million Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

Handelsbanken Fonder AB bought a new position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,400 shares of the company’s stock, valued at approximately $1,041,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Morgan Stanley boosted its stake in Structure Therapeutics by 261.4% in the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after buying an additional 1,510,093 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Structure Therapeutics by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after acquiring an additional 1,432,797 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Structure Therapeutics by 477.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock valued at $116,228,000 after acquiring an additional 1,381,745 shares during the period. Avoro Capital Advisors LLC boosted its stake in shares of Structure Therapeutics by 21.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after purchasing an additional 1,150,000 shares in the last quarter. Finally, Capitolis Liquid Global Markets LLC acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at $61,086,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Up 1.1%

Structure Therapeutics stock opened at $54.13 on Thursday. The stock has a 50-day simple moving average of $50.03 and a 200 day simple moving average of $51.89. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of -54.13 and a beta of -1.43. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $18.26 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, sell-side analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. HC Wainwright dropped their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Citizens Jmp decreased their price objective on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research note on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a research note on Friday, August 7th. Finally, Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.91.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.